FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2040332624> ?p ?o ?g. }

• W2040332624 endingPage "106" @default.
• W2040332624 startingPage "100" @default.
• W2040332624 abstract "Background The prognostic value of occurrence of ischemic stroke in a patient despite aspirin treatment (aspirin treatment failure) is not known. Our objective was to determine if aspirin treatment failure predicts recurrent ischemic stroke and/or death. Methods We performed a post-hoc analysis of data from the National Institute of Neurological Disorders and Stroke (NINDS) intravenous recombinant tissue plasminogen activator (rt-PA) trial and the Trial of ORG 10172 in Acute Stroke Treatment (TOAST). Multivariate analysis was used to calculate the odds ratio (OR) of recurrent stroke and recurrent stroke or death for aspirin treatment failure patients for the duration of available follow-up (3 months for TOAST patients; 12 months for NINDS rt-PA trial patients). Results The rate of aspirin treatment failure was 40% and 35% among 1275 patients and 624 patients recruited in the TOAST and NINDS rt-PA trials, respectively. The risk of stroke and death at 3 months and 1 year was not higher among patients classified as aspirin treatment failures among the TOAST (OR 1.1; 95% confidence interval [CI] 0.8-1.6; P = .7) or NINDS rt-PA trial patients (OR 0.8; 95% CI 0.6-1.3; P = .4), respectively. In subgroup analysis, aspirin treatment failure was not found to be associated with recurrent stroke or with the combined endpoint of stroke and death among categories defined by etiologic subtype, including those with large artery atherosclerosis. Conclusions In a post-hoc analysis of 2 randomized ischemic stroke trials, aspirin treatment failure was not found to be associated with an increased risk of recurrent stroke or death. The prognostic value of occurrence of ischemic stroke in a patient despite aspirin treatment (aspirin treatment failure) is not known. Our objective was to determine if aspirin treatment failure predicts recurrent ischemic stroke and/or death. We performed a post-hoc analysis of data from the National Institute of Neurological Disorders and Stroke (NINDS) intravenous recombinant tissue plasminogen activator (rt-PA) trial and the Trial of ORG 10172 in Acute Stroke Treatment (TOAST). Multivariate analysis was used to calculate the odds ratio (OR) of recurrent stroke and recurrent stroke or death for aspirin treatment failure patients for the duration of available follow-up (3 months for TOAST patients; 12 months for NINDS rt-PA trial patients). The rate of aspirin treatment failure was 40% and 35% among 1275 patients and 624 patients recruited in the TOAST and NINDS rt-PA trials, respectively. The risk of stroke and death at 3 months and 1 year was not higher among patients classified as aspirin treatment failures among the TOAST (OR 1.1; 95% confidence interval [CI] 0.8-1.6; P = .7) or NINDS rt-PA trial patients (OR 0.8; 95% CI 0.6-1.3; P = .4), respectively. In subgroup analysis, aspirin treatment failure was not found to be associated with recurrent stroke or with the combined endpoint of stroke and death among categories defined by etiologic subtype, including those with large artery atherosclerosis. In a post-hoc analysis of 2 randomized ischemic stroke trials, aspirin treatment failure was not found to be associated with an increased risk of recurrent stroke or death." @default.
• W2040332624 created "2016-06-24" @default.
• W2040332624 creator A5001606804 @default.
• W2040332624 creator A5020049468 @default.
• W2040332624 creator A5029167216 @default.
• W2040332624 creator A5031515662 @default.
• W2040332624 creator A5042761081 @default.
• W2040332624 creator A5048570164 @default.
• W2040332624 creator A5051808213 @default.
• W2040332624 creator A5056692177 @default.
• W2040332624 date "2013-02-01" @default.
• W2040332624 modified "2023-09-30" @default.
• W2040332624 title "Aspirin Treatment Failure and the Risk of Recurrent Stroke and Death Among Patients with Ischemic Stroke" @default.
• W2040332624 cites W13025780 @default.
• W2040332624 cites W1993922806 @default.
• W2040332624 cites W1995318104 @default.
• W2040332624 cites W2005882777 @default.
• W2040332624 cites W2007046037 @default.
• W2040332624 cites W2007675502 @default.
• W2040332624 cites W2017453532 @default.
• W2040332624 cites W2024237851 @default.
• W2040332624 cites W2024352468 @default.
• W2040332624 cites W2027538725 @default.
• W2040332624 cites W2038031767 @default.
• W2040332624 cites W2042232724 @default.
• W2040332624 cites W2050552371 @default.
• W2040332624 cites W2059064084 @default.
• W2040332624 cites W2076573584 @default.
• W2040332624 cites W2083061851 @default.
• W2040332624 cites W2083134865 @default.
• W2040332624 cites W2088549042 @default.
• W2040332624 cites W2096428391 @default.
• W2040332624 cites W2099395511 @default.
• W2040332624 cites W2128630796 @default.
• W2040332624 cites W2138595885 @default.
• W2040332624 cites W2140261980 @default.
• W2040332624 cites W2146631984 @default.
• W2040332624 cites W2156641763 @default.
• W2040332624 cites W2161043271 @default.
• W2040332624 cites W2167806412 @default.
• W2040332624 cites W2318352361 @default.
• W2040332624 cites W2341972145 @default.
• W2040332624 cites W4240019765 @default.
• W2040332624 cites W4252748686 @default.
• W2040332624 cites W4254850923 @default.
• W2040332624 doi "https://doi.org/10.1016/j.jstrokecerebrovasdis.2011.06.017" @default.
• W2040332624 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5619691" @default.
• W2040332624 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21835634" @default.
• W2040332624 hasPublicationYear "2013" @default.
• W2040332624 type Work @default.
• W2040332624 sameAs 2040332624 @default.
• W2040332624 citedByCount "11" @default.
• W2040332624 countsByYear W20403326242012 @default.
• W2040332624 countsByYear W20403326242013 @default.
• W2040332624 countsByYear W20403326242014 @default.
• W2040332624 countsByYear W20403326242015 @default.
• W2040332624 countsByYear W20403326242016 @default.
• W2040332624 countsByYear W20403326242019 @default.
• W2040332624 countsByYear W20403326242023 @default.
• W2040332624 crossrefType "journal-article" @default.
• W2040332624 hasAuthorship W2040332624A5001606804 @default.
• W2040332624 hasAuthorship W2040332624A5020049468 @default.
• W2040332624 hasAuthorship W2040332624A5029167216 @default.
• W2040332624 hasAuthorship W2040332624A5031515662 @default.
• W2040332624 hasAuthorship W2040332624A5042761081 @default.
• W2040332624 hasAuthorship W2040332624A5048570164 @default.
• W2040332624 hasAuthorship W2040332624A5051808213 @default.
• W2040332624 hasAuthorship W2040332624A5056692177 @default.
• W2040332624 hasBestOaLocation W20403326242 @default.
• W2040332624 hasConcept C126322002 @default.
• W2040332624 hasConcept C127413603 @default.
• W2040332624 hasConcept C141071460 @default.
• W2040332624 hasConcept C156957248 @default.
• W2040332624 hasConcept C168563851 @default.
• W2040332624 hasConcept C2777628954 @default.
• W2040332624 hasConcept C2780645631 @default.
• W2040332624 hasConcept C44249647 @default.
• W2040332624 hasConcept C67761136 @default.
• W2040332624 hasConcept C71924100 @default.
• W2040332624 hasConcept C78519656 @default.
• W2040332624 hasConceptScore W2040332624C126322002 @default.
• W2040332624 hasConceptScore W2040332624C127413603 @default.
• W2040332624 hasConceptScore W2040332624C141071460 @default.
• W2040332624 hasConceptScore W2040332624C156957248 @default.
• W2040332624 hasConceptScore W2040332624C168563851 @default.
• W2040332624 hasConceptScore W2040332624C2777628954 @default.
• W2040332624 hasConceptScore W2040332624C2780645631 @default.
• W2040332624 hasConceptScore W2040332624C44249647 @default.
• W2040332624 hasConceptScore W2040332624C67761136 @default.
• W2040332624 hasConceptScore W2040332624C71924100 @default.
• W2040332624 hasConceptScore W2040332624C78519656 @default.
• W2040332624 hasIssue "2" @default.
• W2040332624 hasLocation W20403326241 @default.
• W2040332624 hasLocation W20403326242 @default.
• W2040332624 hasLocation W20403326243 @default.
• W2040332624 hasLocation W20403326244 @default.
• W2040332624 hasOpenAccess W2040332624 @default.
• W2040332624 hasPrimaryLocation W20403326241 @default.

• next